Levosimendan treatment of severe acute congestive heart failure refractory to dobutamine/milrinone in children | Zendy

Sergej Prijić | Zendy; Sanja Rakić | Zendy; Ljubica Nikolic | Zendy; Bosiljka Jovicic | Zendy; Mila Stajević | Zendy; Vladislav Vukomanović | Zendy; Jovan Košutić | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Levosimendan treatment of severe acute congestive heart failure refractory to dobutamine/milrinone in children

Author(s) -

Sergej Prijić,

Sanja Rakić,

Ljubica Nikolic,

Bosiljka Jovicic,

Mila Stajević,

Vladislav Vukomanović,

Jovan Košutić

Publication year - 2011

Publication title -

vojnosanitetski pregled

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.123

H-Index - 19

eISSN - 2406-0720

pISSN - 0042-8450

DOI - 10.2298/vsp1111979p

Subject(s) - levosimendan , medicine , dobutamine , cardiology , heart failure , inotrope , preload , milrinone , ejection fraction , afterload , cardiac index , anesthesia , cardiac output , hemodynamics

Levosimendan is a novel positive inotropic agent which, improves myocardial contractility through its calcium-sensitizing action, without causing an increase in myocardial oxygen demand. Also, by opening ATP-sensitive potassium channels, it causes vasodilatation with the reduction in both afterload and preload. Because of the long half-life, its effects last for up 7 to 9 days after 24-hour infusion.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research